- Home
- BQ vs GRI Comparison
BQ vs GRI Comparison
Compare BQ & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- GRI
- Stock Information
- Founded
- BQ 2008
- GRI 2018
- Country
- BQ China
- GRI United States
- Employees
- BQ N/A
- GRI N/A
- Industry
- BQ Other Specialty Stores
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- GRI Health Care
- Exchange
- BQ Nasdaq
- GRI Nasdaq
- Market Cap
- BQ 5.7M
- GRI 6.1M
- IPO Year
- BQ 2020
- GRI N/A
- Fundamental
- Price
- BQ $0.32
- GRI $0.78
- Analyst Decision
- BQ
- GRI Strong Buy
- Analyst Count
- BQ 0
- GRI 2
- Target Price
- BQ N/A
- GRI $11.50
- AVG Volume (30 Days)
- BQ 198.4K
- GRI 377.5K
- Earning Date
- BQ 12-31-2024
- GRI 11-14-2024
- Dividend Yield
- BQ N/A
- GRI N/A
- EPS Growth
- BQ N/A
- GRI N/A
- EPS
- BQ N/A
- GRI N/A
- Revenue
- BQ $98,241,396.00
- GRI N/A
- Revenue This Year
- BQ N/A
- GRI N/A
- Revenue Next Year
- BQ N/A
- GRI N/A
- P/E Ratio
- BQ N/A
- GRI N/A
- Revenue Growth
- BQ N/A
- GRI N/A
- 52 Week Low
- BQ $0.22
- GRI $0.30
- 52 Week High
- BQ $0.74
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- BQ 33.12
- GRI 49.02
- Support Level
- BQ $0.32
- GRI $0.75
- Resistance Level
- BQ $0.38
- GRI $1.00
- Average True Range (ATR)
- BQ 0.03
- GRI 0.09
- MACD
- BQ -0.01
- GRI -0.00
- Stochastic Oscillator
- BQ 4.48
- GRI 38.93
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.